Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
Recruiting
The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma. Study details include: * The study duration will be up to 15 weeks. * The treatment duration will be 12 weeks. * The visit frequency will be once every 4 weeks, with 3 clinic visits and 2 video calls in total.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/18/2025
Locations: Research Site, Phoenix, Arizona +18 locations
Conditions: Mild Asthma
Evaluation of Biomarkers for Predicting Macronutrient Intake
Recruiting
The goal of this clinical trial is to establish the relationship between macronutrient food intake and the resulting blood and intersticial fluid (ISF )levels of small molecule markers, as well as, validate wearable optical readers and data fusion algorithms to accurately predict individual-specific macronutrient availability in real time. The study involves 1 screening visit of approximately 2 hours and up to 4 study days of approximately 14 hours. Subjects will be asked to arrive in the faste... Read More
Gender:
ALL
Ages:
Between 50 years and 75 years
Trial Updated:
07/18/2025
Locations: Center for Translational Research in Aging & Longevity, College Station, Texas
Conditions: Glucose Metabolism, Amino Acid Metabolism
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruiting
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approxi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +135 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)
Recruiting
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. It is known to cause a variety of cancers including cancer of the cervix. Even though there are ways to detect cervical cancer early, many individuals do not un... Read More
Gender:
FEMALE
Ages:
25 years and above
Trial Updated:
07/18/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +24 locations
Conditions: Cervical Carcinoma, Human Papillomavirus Infection
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Recruiting
The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Michael G Oefelein Clinical Trials ( Site 0053), Bakersfield, California +10 locations
Conditions: Non-Muscle Invasive Bladder Cancer
Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy
Recruiting
the investigators will pursue two specific aims: (1) to monitor the extent of heme oxygenase induction (by measuring endogenous CO production) in relationship to the extent of hepatic resection (2) to assess the production of CO in patients following liver resection and correlate these findings to the rate of liver regeneration and liver function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Englewood Hospital, Englewood, New Jersey
Conditions: Liver Cancer Adult, Liver Regeneration
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Recruiting
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Dana-Farber Cancer Institute ( Site 0050), Boston, Massachusetts +10 locations
Conditions: Breast Neoplasms, Breast Cancer
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Recruiting
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: SCRI - Arizona Oncology Associates, PC-HOPE, Tucson, Arizona +27 locations
Conditions: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Recruiting
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/18/2025
Locations: Florida Cancer Specialists, Fort Myers, Florida +11 locations
Conditions: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
Recruiting
The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/18/2025
Locations: The University of Alabama, Tuscaloosa, Alabama +26 locations
Conditions: Obstructive Sleep Apnea, Hypertension
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Recruiting
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/18/2025
Locations: Headlands Research - Scottsdale, Scottsdale, Arizona +26 locations
Conditions: Alcohol Use Disorder
Innovative Automated Insulin Delivery System for Type 2 Diabetes
Recruiting
The goal of this clinical trial is to learn if the twiist insulin delivery system works to treat adults with insulin-treated type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: Scripps Whittier Diabetes Institute, La Jolla, California +23 locations
Conditions: Type 2 Diabetes, Insulin Treated Type 2 Diabetes Mellitus